Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Incannex Healthcare (IHL) has partnered with the Monash Trauma Group to study the proactive effects of IHL-216A in sports concession
  • Last year, an initial in vivo study of the Inncanex’s proprietary drug — which combines CBD and an anaesthetic agent isoflurane — yielded positive results
  • The study with Monash Trauma Group will use a model of traumatic brain injury developed by the U.S. NFL and will evaluate the treatment in rodents
  • Should the study demonstrate the effectiveness of the drug, which has also been developed in accordance with global and Australian anti-doping codes Incannex will be able to proceed to a pivotal Phase 2 trial in humans
  • Shares last traded at 20 cents

Incannex Healthcare (IHL) has partnered with the Monash Trauma Group to study the proactive effects of its proprietary drug IHL-216A in sports concession.

Traumatic Brain Injury (TBI) is a major focus of the Monash Trauma Group, a team of principle investigators at Monash University’s Department of Neuroscience.

The drug, IHL-216A, combines cannabidiol (CBD) with a volatile anaesthetic agent isoflurane. As it’s being developed for sports concussions, the drug has been developed in accordance with global and Australian anti-doping specifications.

The study with Monash Trauma Group will use a model of traumatic brain injury developed by the U.S. National Football League and evaluate the treatment in rodents.

If it yields positive results, the in vivo study will also serve as a precursor to a pivotal in-human Phase 2 study, as CEO and Managing Director Joel Latham explained.

“Undertaking this extensive and well-recognised animal model study, instead of the in-human proof of concept study, has the effect of reducing the overall development time and expense associated with our drug registration plan.”

“Furthermore, the company will collect additional data from an animal study that it would not be able to compile in human studies. This additional data will inform the design and end points of our pivotal clinical trials,” he added.

Last year, an initial in vivo study of IHL-216A found Incannex’s combination drug was more effective than CBD alone at reducing neuronal damage, neuroinflammation and behavioural issues associated with TBI.

Shares last traded at 20 cents on Wednesday 10, March 2021.

IHL by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) shuffles board

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.